Who is sponsoring NCT02499497?

NCT02499497 is sponsored by Dana-Farber Cancer Institute.

What condition does NCT02499497 study?

NCT02499497 studies Prostate Cancer.

What drugs are being tested in NCT02499497?

Interventions: LY2452473, Placebo.

What is the status of NCT02499497?

NCT02499497 is currently COMPLETED.

Last reviewed 2021-09-28 · How we verify

A Selective Androgen Receptor Modulator for Symptom Management in Prostate Cancer

NCT02499497 PHASE2 COMPLETED Results posted

This research study is studying the use of a targeted therapy called LY SARM, which is an investigational drug from a new class of molecules called Selective Androgen Receptor Modulators (SARMs) as a possible improvement in quality of life for participants who have undergone radical prostatectomy. Androgens are a group of hormones that play a role in male traits and reproductive activity. The names of the study interventions involved in this study are: \- LY2452473

Details

Lead sponsor	Dana-Farber Cancer Institute
Phase	PHASE2
Status	COMPLETED
Enrolment	114
Start date	Mon Feb 29 2016 00:00:00 GMT+0000 (Coordinated Universal Time)
Completion	Sat Oct 31 2020 00:00:00 GMT+0000 (Coordinated Universal Time)

Conditions

Prostate Cancer

Interventions

LY2452473
Placebo

Countries

United States